TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the la
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-30 3:05 AM EDT | TempraMed Technologies Ltd.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026"). Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-29 4:29 PM EDT | Elite Pharmaceuticals, Inc.
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporati
Biotechnology, Pharmaceuticals, Retail
2026-06-29 7:15 AM EDT | PharmaCorp RX Inc.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks a
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-26 4:10 PM EDT | TempraMed Technologies Ltd.
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at
Biotechnology, Pharmaceuticals, Health
2026-06-26 8:47 AM EDT | Hemostemix Inc.
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has completed two significant milestones on its projected path to market scale and operational excellence. United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, which the Company believes are among the most pow
2026-06-26 8:00 AM EDT | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
Gaithersburg, Maryland--(Newsfile Corp. - June 25, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining and digital infrastructure company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle"), has initiated an evaluation of proprietary data centre and power generation opportunities designed to support long-term DOGE mining operations and future AI infrastructure workloads. Alongside this exploration, t
2026-06-25 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in
2026-06-25 8:00 AM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Strategic Leadership Appointments to Support Continued Growth and Regulatory Excellence
Robert Guzman has been appointed Chief Compliance & Regulatory Officer, bringing extensive experience in regulatory oversight, compliance management, and quality assurance to strengthen Custom Health's governance framework and support the Company's continued expansion across highly regulated healthcare and pharmacy markets. Brent Herman, Founder, President and Chief Executive Officer of InnovativeRx US Holdings, Inc., has been appointed Executive Vice President, Cor
Technology, Pharmaceuticals, Health
2026-06-25 6:30 AM EDT | Custom Health Holdings Inc.
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations to Attend Fastmarkets Global Lithium, Battery & Critical Materials in Las Vegas
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to announce that it will be attending the Fastmarkets Global Lithium, Battery & Critical Materials conference in Las Vegas, Nevada from June 23-2
Technology, Chemical, Pharmaceuticals
2026-06-23 8:00 AM EDT | Telescope Innovations Corp.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. St
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-23 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Custom Health Holdings Inc. to Commence Trading on the Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - Custom Health Holdings Inc. (TSX: CHLT) (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated June 5, 2026, is pleased to announce that it has received final approval for listing on the Toronto Stock Exchange (the "TSX"). The common shares of the Company (CUSIP 23204J104 / ISIN CA23204J1049) ("Common Shares") will commence trading on the TSX un
Technology, Pharmaceuticals, Health
2026-06-22 5:45 PM EDT | Custom Health Holdings Inc.
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache
2026-06-22 8:00 AM EDT | BetterLife Pharma Inc.
Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)
Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers,
Biotechnology, Pharmaceuticals
2026-06-22 7:51 AM EDT | Yellowbird Diagnostics
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operatio
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-22 7:00 AM EDT | Cannabis Bioscience International Holdings
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators ("CSA"), the pilot program under
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-19 12:16 PM EDT | Neural Therapeutics Inc.